Measuring symptom experience of side-effects of immunosuppressive drugs: The Modified Transplant Symptom Occurrence and Distress Scale

Transplant International

Volumn 21, Issue 8, 2008, Pages 764-773

  Dobbels, Fabienne ^a   Moons, Philip ^a   Abraham, Ivo ^b,c   Larsen, Christian P ^d   Dupont, Lieven ^e   De Geest, Sabina ^a,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b University of Pennsylvania ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Immunosuppression; Organ transplantation; Patient reported outcomes; Side effects; Symptom experience

Indexed keywords

AZATHIOPRINE; BELATACEPT; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTENT VALIDITY; DEPRESSION; DISCRIMINANT VALIDITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODIFIED TRANSPLANT SYMPTOM OCCURRENCE AND SYMPTOM; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUESTIONNAIRE; SYMPTOM DISTRESS SCALE; MIDDLE AGED; VALIDATION STUDY;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 58149197847     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00674.x     Document Type: Article

References (38)

1. Doward LC, McKenna SP. Defining patient-reported outcomes. Value Health 2004; 7(Suppl. 1): S4.
2. McKenna SP, Doward LC. Integrating patient-reported outcomes. Value Health 2004; 7(Suppl. 1): S9.
3. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: Report of the ISPOR Task Force for translation and cultural adaptation. Value Health 2005; 8: 94.
4. Webster AC, Woodroffe C, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosup-pression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005; 331: 810.
5. Teixeira de Barros C, Cabrita J. Noncompliance with immunosuppressive therapy: prevalence and determinants. Transplant Proc 2000; 32: 2633.
6. Moons P, De Geest S, Abraham I, Van Cleemput J, Vanhaecke J. Symptom experience associated with maintenance immunosuppression after heart transplantation: patients' appraisal of side effects. Heart Lung 1998; 27: 315.
7. Moons P, Fairchild S, De Geest S. Patients' appraisal of side effects in quality of life assessments of immunosuppressive regimens. In: Cochat P, ed. Immunosuppression Under Trial. Dordrecht, the Netherlands: Kluwer Academic Publishing, 1999: 69 pp.
8. Moons P, De Geest S, Versteven K, et al. Psychometric properties of the "Modified Transplant Symptom Occurrence and Symptom Distress Scale". J Nurs Meas 2001; 9: 115.
9. Moons P, Vanrenterghem Y, van Hooff JP, et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen: a multicentre study. Transplant Proc 2002; 34: 1691.
10. Cleemput I, Kesteloot K, Moons P, et al. The construct and concurrent validity of the EQ-5D in a renal transplant population. Value Health 2004; 7: 499.
11. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function, and cardiovascular risk. Am J Transplant 2004; 4: 937.
12. De Geest S, Abraham I, Moons P, et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998; 17: 854.
13. De Geest S, Moons P. The patient's appraisal of side-effects: the blind spot in quality-of-life assessments in transplant recipients. Nephrol Dial Transplant 2000; 15: 457.
14. Burra P, de Bona M. Quality of life following organ transplantation. Transpl Int 2007; 20: 397.
15. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19: 607.
16. Anderson RB, Testa MA. Symptom distress checklists as a component of quality of life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician. Drug Inf J 1994; 28: 89.
17. Cuervo LG, Clarke M. Balancing benefits and harms in health care. BMJ 2003; 327: 65.
18. Moons P, Vanrentherghem Y, van Hooff JP, et al. Health-related quality of life and symptom experience in tacrolimus-based regimens after renal transplantation: a multicentre study. Transpl Int 2003; 16: 653.
19. Leventhal H, Johnson JE. Laboratory and field experimentation: Development of a theory of self-regulation. In: Wooldridge PJ, Schmitt MH, Schipper JK, Leonard RC, eds. Behavioral Science and Nursing Theory. St Louis, MO: CV Mosby, 1983: 189-262.
20. Rhodes VA, Watson PM. Symptom distress, the concept: past and present. Semin Oncol 1987; 3: 242.
21. MacNaughton KL, Rodrigue JR, Cicale M, Staples EM. Health-related quality of life and symptom frequency before and after lung transplantation. Clin Transplant 1998; 12: 320.
22. Winsett RP, Arheart K, Stratta RJ, et al. Evaluation of an immunosuppressant side effect instrument. Prog Transplant 2004; 14: 210.
23. Matthees BJ, Anantachoti P, Kreitzer MJ, Savik K, Hertz MI, Gross CR. Use of complementary therapies, adherence, and quality of life in lung transplant recipients. Heart Lung 2001; 30: 258.
24. Unal G, de Boer JB, Borsboom GJ, Brouwer JT, Essink-Bot M, de Man RA. A psychometric comparison of health-related quality of life measures in chronic liver disease. 7 Clin Epidemiol 2001; 54: 587.
25. Franke GH, Reimer J, Kohnle M, Luetkes P, Maehner N, Heemann U. Quality of life in end-stage renal disease patients after successful kidney transplantation: development of the ESRD symptom checklist - transplantation module. Nephron 1999; 83: 31.
26. Grady KL, Jalowiec A, Grusk BB, White-Williams C, Robinson JA. Symptom distress in cardiac transplant candidates. Heart Lung 1992; 21: 434.
27. De Vito Dabbs A, Hoffman LA, Dauber JH, Zullo T, Iacono AT. Evaluating the reliability and validity of the Questionnaire for Lung Transplant Patients. Prog Transplant 2002; 12: 191.
28. De Vito DA, Kim Y, Vensak J, Studer S, Iacono A. Validation and refinement of the Questionnaire for Lung Transplant Patients. Prog Transplant 2004; 14: 338.
29. Hathaway D, Winsett R, Prendergast M, Subaiya I. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens. Clin Transplant 2003; 17: 183.
30. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
31. Gijsbers van Wijk CM, Kolk AM. Sex differences in physical symptoms: The contribution of symptom perception theory. Soc Sci Med 1997; 45: 231.
32. Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med 1998; 60: 150.
33. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1913; 67: 361.
34. Sermeus W, Delesie L. Ridit analysis on ordinal data. West JNurs Res 1996; 18: 351.
35. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004; 25: 535.
36. Russ G, Jamieson J, Oberbauer J, et al. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine. Transpl Int 2007; 20: 875.
37. Magliocca JF, Knechtle SJ. The evolving role of alemtuzu-mab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705.
38. Becker YT, Samangieo-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19: 621.